Through a non-exclusive agreement, ARUP will offer Predictive’s CertNDxTM Bladder Cancer Assays in its comprehensive test menu to leading hospitals, healthcare providers, academic medical centers and military and government facilities around the country. ARUP’s clients will be able to order CertNDx testing, submit samples and receive all results through ARUP. Predictive Biosciences will run the diagnostic testing in its CAP and CLIA-certified laboratory.
“We are excited to begin our partnership with ARUP, a laboratory that shares our passion for innovation and technology. We believe this alliance will greatly expand the availability of our bladder cancer products to a wider network of leading medical facilities that can benefit from CertNDx testing,” said Pierre Cassigneul, chief executive officer at Predictive Biosciences.
The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence post treatment. The test’s unique approach stratifies patients based on their likelihood of bladder cancer and is highly accurate across all stages and grades of bladder cancer. CertNDx testing is also available in a tissue-based prognostic test for molecular grading that can provide a quantitative molecular assessment of tumor grade including the likelihood of disease progression.